Annual EBITDA
$690.00 M
-$868.00 M-55.71%
December 31, 2024
Summary
- As of February 6, 2025, TEVA annual EBITDA is $690.00 million, with the most recent change of -$868.00 million (-55.71%) on December 31, 2024.
- During the last 3 years, TEVA annual EBITDA has fallen by -$2.19 billion (-76.03%).
- TEVA annual EBITDA is now -87.33% below its all-time high of $5.45 billion, reached on December 31, 2014.
Performance
TEVA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$246.00 M
+$39.00 M+18.84%
December 31, 2024
Summary
- As of February 6, 2025, TEVA quarterly EBITDA is $246.00 million, with the most recent change of +$39.00 million (+18.84%) on December 31, 2024.
- Over the past year, TEVA quarterly EBITDA has increased by +$191.00 million (+347.27%).
- TEVA quarterly EBITDA is now -87.89% below its all-time high of $2.03 billion, reached on March 31, 2018.
Performance
TEVA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$762.00 M
-$748.00 M-49.54%
December 31, 2024
Summary
- As of February 6, 2025, TEVA TTM EBITDA is $762.00 million, with the most recent change of -$748.00 million (-49.54%) on December 31, 2024.
- Over the past year, TEVA TTM EBITDA has dropped by -$559.00 million (-42.32%).
- TEVA TTM EBITDA is now -86.01% below its all-time high of $5.45 billion, reached on December 31, 2014.
Performance
TEVA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TEVA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -55.7% | +347.3% | -42.3% |
| 3 y3 years | -76.0% | +141.6% | +277.2% |
| 5 y5 years | -46.0% | -71.7% | +139.1% |
TEVA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.0% | +174.6% | -75.3% | +136.0% | -73.5% | +182.3% |
| 5 y | 5-year | -76.0% | +135.4% | -75.3% | +106.2% | -78.3% | +133.8% |
| alltime | all time | -87.3% | +104.5% | -87.9% | +102.0% | -86.0% | +105.0% |
Teva Pharmaceutical Industries Limited EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $690.00 M(-55.7%) | $246.00 M(+18.8%) | $762.00 M(-49.5%) |
| Sep 2024 | - | $207.00 M(-18.5%) | $1.51 B(-21.8%) |
| Jun 2024 | - | $254.00 M(+361.8%) | $1.93 B(+46.1%) |
| Mar 2024 | - | $55.00 M(-94.5%) | $1.32 B(-15.2%) |
| Dec 2023 | $1.56 B(-268.4%) | $994.00 M(+58.5%) | $1.56 B(-1398.3%) |
| Sep 2023 | - | $627.00 M(-276.6%) | -$120.00 M(+1400.0%) |
| Jun 2023 | - | -$355.00 M(-221.6%) | -$8.00 M(-96.7%) |
| Mar 2023 | - | $292.00 M(-142.7%) | -$244.00 M(-73.7%) |
| Dec 2022 | -$925.00 M(-132.1%) | -$684.00 M(-192.6%) | -$926.00 M(+8318.2%) |
| Sep 2022 | - | $739.00 M(-225.0%) | -$11.00 M(-105.4%) |
| Jun 2022 | - | -$591.00 M(+51.5%) | $202.00 M(-88.0%) |
| Mar 2022 | - | -$390.00 M(-268.8%) | $1.68 B(-41.7%) |
| Dec 2021 | $2.88 B(-247.8%) | $231.00 M(-75.7%) | $2.88 B(-18.1%) |
| Sep 2021 | - | $952.00 M(+7.3%) | $3.52 B(-351.9%) |
| Jun 2021 | - | $887.00 M(+9.5%) | -$1.40 B(-19.3%) |
| Mar 2021 | - | $810.00 M(-6.7%) | -$1.73 B(-11.3%) |
| Dec 2020 | -$1.95 B(-252.3%) | $868.00 M(-121.9%) | -$1.95 B(-13.5%) |
| Sep 2020 | - | -$3.96 B(-815.0%) | -$2.25 B(-210.4%) |
| Jun 2020 | - | $554.00 M(-6.1%) | $2.04 B(+57.9%) |
| Mar 2020 | - | $590.00 M(+4.6%) | $1.29 B(+1.0%) |
| Dec 2019 | $1.28 B(+670.5%) | $564.00 M(+69.9%) | $1.28 B(-160.7%) |
| Sep 2019 | - | $332.00 M(-271.1%) | -$2.11 B(+8.1%) |
| Jun 2019 | - | -$194.00 M(-133.6%) | -$1.95 B(+51.1%) |
| Mar 2019 | - | $577.00 M(-120.5%) | -$1.29 B(-876.5%) |
| Dec 2018 | $166.00 M(-101.1%) | -$2.82 B(-675.7%) | $166.00 M(-101.7%) |
| Sep 2018 | - | $490.00 M(+5.4%) | -$9.52 B(+4.6%) |
| Jun 2018 | - | $465.00 M(-77.1%) | -$9.11 B(-38.2%) |
| Mar 2018 | - | $2.03 B(-116.2%) | -$14.73 B(-4.3%) |
| Dec 2017 | -$15.39 B(-631.9%) | -$12.51 B(-1482.2%) | -$15.39 B(+343.3%) |
| Sep 2017 | - | $905.00 M(-117.5%) | -$3.47 B(-3.9%) |
| Jun 2017 | - | -$5.16 B(-475.5%) | -$3.61 B(-288.9%) |
| Mar 2017 | - | $1.38 B(-333.4%) | $1.91 B(-4.7%) |
| Dec 2016 | $2.89 B(-26.4%) | -$589.00 M(-177.0%) | $2.01 B(-35.9%) |
| Sep 2016 | - | $765.00 M(+111.9%) | $3.13 B(-15.2%) |
| Jun 2016 | - | $361.00 M(-75.4%) | $3.69 B(-14.5%) |
| Mar 2016 | - | $1.47 B(+174.3%) | $4.32 B(+9.8%) |
| Dec 2015 | $3.93 B(-27.8%) | $536.00 M(-59.5%) | $3.93 B(-16.2%) |
| Sep 2015 | - | $1.32 B(+34.5%) | $4.69 B(-3.1%) |
| Jun 2015 | - | $985.00 M(-9.1%) | $4.84 B(-6.1%) |
| Mar 2015 | - | $1.08 B(-16.5%) | $5.15 B(-5.4%) |
| Dec 2014 | $5.45 B(+69.9%) | $1.30 B(-11.9%) | $5.45 B(+7.6%) |
| Sep 2014 | - | $1.47 B(+13.4%) | $5.06 B(+5.3%) |
| Jun 2014 | - | $1.30 B(-5.6%) | $4.81 B(+44.7%) |
| Mar 2014 | - | $1.38 B(+51.0%) | $3.32 B(+3.6%) |
| Dec 2013 | $3.21 B(-17.4%) | $911.00 M(-25.3%) | $3.21 B(+7.3%) |
| Sep 2013 | - | $1.22 B(-755.9%) | $2.99 B(+41.0%) |
| Jun 2013 | - | -$186.00 M(-114.8%) | $2.12 B(-42.7%) |
| Mar 2013 | - | $1.26 B(+82.2%) | $3.70 B(-4.8%) |
| Dec 2012 | $3.88 B(-8.9%) | $692.00 M(+96.6%) | $3.88 B(-7.9%) |
| Sep 2012 | - | $352.00 M(-74.7%) | $4.21 B(-18.1%) |
| Jun 2012 | - | $1.39 B(-3.9%) | $5.14 B(+6.2%) |
| Mar 2012 | - | $1.45 B(+41.4%) | $4.84 B(+6.9%) |
| Dec 2011 | $4.26 B(-11.7%) | $1.02 B(-20.2%) | $4.53 B(+0.5%) |
| Sep 2011 | - | $1.28 B(+17.3%) | $4.51 B(-3.5%) |
| Jun 2011 | - | $1.09 B(-3.5%) | $4.67 B(-4.4%) |
| Mar 2011 | - | $1.13 B(+13.2%) | $4.89 B(+1.3%) |
| Dec 2010 | $4.83 B(+45.6%) | $1.00 B(-30.8%) | $4.83 B(+7.8%) |
| Sep 2010 | - | $1.45 B(+10.6%) | $4.48 B(+10.9%) |
| Jun 2010 | - | $1.31 B(+22.4%) | $4.04 B(+17.7%) |
| Mar 2010 | - | $1.07 B(+64.0%) | $3.43 B(+18.3%) |
| Dec 2009 | $3.31 B(+102.3%) | $652.00 M(-35.3%) | $2.90 B(+87.9%) |
| Sep 2009 | - | $1.01 B(+43.4%) | $1.54 B(+17.5%) |
| Jun 2009 | - | $702.00 M(+30.5%) | $1.31 B(-4.2%) |
| Mar 2009 | - | $538.00 M(-176.4%) | $1.37 B(-16.3%) |
| Dec 2008 | $1.64 B(-43.8%) | -$704.00 M(-190.6%) | $1.64 B(-47.9%) |
| Sep 2008 | - | $777.00 M(+2.2%) | $3.14 B(+0.4%) |
| Jun 2008 | - | $760.00 M(-5.6%) | $3.13 B(-0.2%) |
| Mar 2008 | - | $805.00 M(+0.5%) | $3.14 B(+7.6%) |
| Dec 2007 | $2.92 B(+15.4%) | $801.00 M(+4.7%) | $2.92 B(+10.4%) |
| Sep 2007 | - | $765.00 M(-0.3%) | $2.64 B(-2.5%) |
| Jun 2007 | - | $767.00 M(+31.6%) | $2.71 B(-1.4%) |
| Mar 2007 | - | $583.00 M(+10.7%) | $2.75 B(+7.4%) |
| Dec 2006 | $2.53 B(+62.5%) | $526.80 M(-36.8%) | $2.56 B(+7.0%) |
| Sep 2006 | - | $833.70 M(+3.6%) | $2.39 B(+27.9%) |
| Jun 2006 | - | $805.10 M(+104.9%) | $1.87 B(+36.1%) |
| Mar 2006 | - | $393.00 M(+9.1%) | $1.37 B(+0.5%) |
| Dec 2005 | $1.55 B | $360.30 M(+15.4%) | $1.37 B(+1.8%) |
| Sep 2005 | - | $312.20 M(+1.2%) | $1.34 B(-0.4%) |
| Jun 2005 | - | $308.60 M(-20.1%) | $1.35 B(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2005 | - | $386.40 M(+15.0%) | $1.34 B(+13.8%) |
| Dec 2004 | $1.39 B(+37.6%) | $336.00 M(+5.8%) | $1.18 B(+10.3%) |
| Sep 2004 | - | $317.70 M(+6.9%) | $1.07 B(+12.8%) |
| Jun 2004 | - | $297.10 M(+32.5%) | $944.90 M(+1.6%) |
| Mar 2004 | - | $224.20 M(-1.0%) | $929.70 M(+5.1%) |
| Dec 2003 | $1.01 B(+63.1%) | $226.50 M(+14.9%) | $884.80 M(+5.2%) |
| Sep 2003 | - | $197.10 M(-30.1%) | $840.90 M(+9.9%) |
| Jun 2003 | - | $281.90 M(+57.2%) | $765.40 M(+28.6%) |
| Mar 2003 | - | $179.30 M(-1.8%) | $595.10 M(+13.6%) |
| Dec 2002 | $620.90 M(+27.9%) | $182.60 M(+50.2%) | $524.00 M(+15.6%) |
| Sep 2002 | - | $121.60 M(+9.0%) | $453.16 M(+5.2%) |
| Jun 2002 | - | $111.60 M(+3.1%) | $430.56 M(+6.1%) |
| Mar 2002 | - | $108.20 M(-3.2%) | $405.81 M(+7.8%) |
| Dec 2001 | $485.58 M(+3.3%) | $111.76 M(+12.9%) | $376.51 M(-14.6%) |
| Sep 2001 | - | $99.00 M(+14.0%) | $440.71 M(+5.9%) |
| Jun 2001 | - | $86.85 M(+10.1%) | $416.13 M(-1.6%) |
| Mar 2001 | - | $78.90 M(-55.2%) | $422.74 M(+5.7%) |
| Dec 2000 | $470.19 M(+40.0%) | $175.95 M(+136.4%) | $399.83 M(+13.0%) |
| Sep 2000 | - | $74.42 M(-20.4%) | $353.94 M(+6.9%) |
| Jun 2000 | - | $93.46 M(+66.9%) | $331.17 M(+17.2%) |
| Mar 2000 | - | $56.00 M(-56.9%) | $282.45 M(+5.6%) |
| Dec 1999 | $335.89 M(+28.0%) | $130.07 M(+151.9%) | $267.37 M(+10.5%) |
| Sep 1999 | - | $51.64 M(+15.4%) | $241.94 M(+5.2%) |
| Jun 1999 | - | $44.74 M(+9.3%) | $229.99 M(+10.1%) |
| Mar 1999 | - | $40.92 M(-60.9%) | $208.85 M(+2.6%) |
| Dec 1998 | $262.48 M(+16.2%) | $104.63 M(+163.6%) | $203.53 M(-136.9%) |
| Sep 1998 | - | $39.70 M(+68.2%) | -$552.30 M(+80.9%) |
| Jun 1998 | - | $23.60 M(-33.7%) | -$305.30 M(+424.5%) |
| Mar 1998 | - | $35.60 M(-105.5%) | -$58.20 M(-133.5%) |
| Dec 1997 | $225.80 M(+30.5%) | -$651.20 M(-327.1%) | $173.80 M(-37.5%) |
| Sep 1997 | - | $286.70 M(+5.9%) | $278.20 M(+22.0%) |
| Jun 1997 | - | $270.70 M(+1.2%) | $228.10 M(+9.9%) |
| Mar 1997 | - | $267.60 M(-148.9%) | $207.60 M(+60.6%) |
| Dec 1996 | $173.00 M(+26.1%) | -$546.80 M(-331.1%) | $129.30 M(-57.7%) |
| Sep 1996 | - | $236.60 M(-5.4%) | $305.50 M(+30.4%) |
| Jun 1996 | - | $250.20 M(+32.2%) | $234.20 M(+66.3%) |
| Mar 1996 | - | $189.30 M(-151.1%) | $140.80 M(+35.1%) |
| Dec 1995 | $137.20 M(+2.2%) | -$370.60 M(-324.2%) | $104.20 M(-31.1%) |
| Sep 1995 | - | $165.30 M(+5.4%) | $151.20 M(+16.8%) |
| Jun 1995 | - | $156.80 M(+2.7%) | $129.40 M(+8.3%) |
| Mar 1995 | - | $152.70 M(-147.2%) | $119.50 M(+15.5%) |
| Dec 1994 | $134.30 M(+24.8%) | -$323.60 M(-325.5%) | $103.50 M(-28.3%) |
| Sep 1994 | - | $143.50 M(-2.3%) | $144.40 M(+12.7%) |
| Jun 1994 | - | $146.90 M(+7.5%) | $128.10 M(+20.6%) |
| Mar 1994 | - | $136.70 M(-148.4%) | $106.20 M(+20.8%) |
| Dec 1993 | $107.60 M(+47.8%) | -$282.70 M(-322.2%) | $87.90 M(-41.6%) |
| Sep 1993 | - | $127.20 M(+1.8%) | $150.50 M(+29.4%) |
| Jun 1993 | - | $125.00 M(+5.6%) | $116.30 M(+38.0%) |
| Mar 1993 | - | $118.40 M(-153.8%) | $84.30 M(+43.4%) |
| Dec 1992 | $72.80 M(+10.5%) | -$220.10 M(-336.7%) | $58.80 M(-32.1%) |
| Sep 1992 | - | $93.00 M(0.0%) | $86.60 M(+19.8%) |
| Jun 1992 | - | $93.00 M(+0.1%) | $72.30 M(+26.6%) |
| Mar 1992 | - | $92.90 M(-148.3%) | $57.10 M(+10.9%) |
| Dec 1991 | $65.90 M(+24.6%) | -$192.30 M(-344.3%) | $51.50 M(-45.8%) |
| Sep 1991 | - | $78.70 M(+1.2%) | $95.00 M(+20.4%) |
| Jun 1991 | - | $77.80 M(-10.9%) | $78.90 M(+11.6%) |
| Mar 1991 | - | $87.30 M(-158.7%) | $70.70 M(+44.0%) |
| Dec 1990 | $52.90 M(+19.4%) | -$148.80 M(-337.7%) | $49.10 M(+6.0%) |
| Sep 1990 | - | $62.60 M(-10.1%) | $46.30 M(-2.5%) |
| Jun 1990 | - | $69.60 M(+5.9%) | $47.50 M(+1.7%) |
| Mar 1990 | - | $65.70 M(-143.3%) | $46.70 M(-5.1%) |
| Dec 1989 | $44.30 M(+46.2%) | -$151.60 M(-337.6%) | $49.20 M(-37.4%) |
| Sep 1989 | - | $63.80 M(-7.3%) | $78.60 M(+28.0%) |
| Jun 1989 | - | $68.80 M(+0.9%) | $61.40 M(+43.8%) |
| Mar 1989 | - | $68.20 M(-155.8%) | $42.70 M(+74.3%) |
| Dec 1988 | $30.30 M(+24.2%) | -$122.20 M(-362.2%) | $24.50 M(-83.3%) |
| Sep 1988 | - | $46.60 M(-7.0%) | $146.70 M(+14.1%) |
| Jun 1988 | - | $50.10 M(+0.2%) | $128.60 M(+22.6%) |
| Mar 1988 | - | $50.00 M(+75.4%) | $104.90 M(+2284.1%) |
| Sep 1987 | - | $28.50 M(+8.0%) | $4.40 M(-59.3%) |
| Jun 1987 | - | $26.40 M(-130.9%) | $10.80 M(-44.0%) |
| Mar 1987 | $24.40 M(+58.4%) | -$85.40 M(-344.7%) | $19.30 M(-60.0%) |
| Dec 1986 | - | $34.90 M(0.0%) | $48.20 M(+33.5%) |
| Sep 1986 | - | $34.90 M(0.0%) | $36.10 M(+50.4%) |
| Jun 1986 | - | $34.90 M(-161.8%) | $24.00 M(+101.7%) |
| Mar 1986 | $15.40 M | -$56.50 M(-347.8%) | $11.90 M(-82.6%) |
| Dec 1985 | - | $22.80 M(0.0%) | $68.40 M(+50.0%) |
| Sep 1985 | - | $22.80 M(0.0%) | $45.60 M(+100.0%) |
| Jun 1985 | - | $22.80 M | $22.80 M |
FAQ
- What is Teva Pharmaceutical Industries Limited annual EBITDA?
- What is the all time high annual EBITDA for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited annual EBITDA year-on-year change?
- What is Teva Pharmaceutical Industries Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited quarterly EBITDA year-on-year change?
- What is Teva Pharmaceutical Industries Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited TTM EBITDA year-on-year change?
What is Teva Pharmaceutical Industries Limited annual EBITDA?
The current annual EBITDA of TEVA is $690.00 M
What is the all time high annual EBITDA for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high annual EBITDA is $5.45 B
What is Teva Pharmaceutical Industries Limited annual EBITDA year-on-year change?
Over the past year, TEVA annual EBITDA has changed by -$868.00 M (-55.71%)
What is Teva Pharmaceutical Industries Limited quarterly EBITDA?
The current quarterly EBITDA of TEVA is $246.00 M
What is the all time high quarterly EBITDA for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high quarterly EBITDA is $2.03 B
What is Teva Pharmaceutical Industries Limited quarterly EBITDA year-on-year change?
Over the past year, TEVA quarterly EBITDA has changed by +$191.00 M (+347.27%)
What is Teva Pharmaceutical Industries Limited TTM EBITDA?
The current TTM EBITDA of TEVA is $762.00 M
What is the all time high TTM EBITDA for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high TTM EBITDA is $5.45 B
What is Teva Pharmaceutical Industries Limited TTM EBITDA year-on-year change?
Over the past year, TEVA TTM EBITDA has changed by -$559.00 M (-42.32%)